Research

Taurine for Longevity

An amino-sulfonic acid with striking animal-aging results and modest cardiometabolic trial signals, but conflicting human biomarker data and no lifespan evidence.

Emerging
Evidence rating
Evidence review

What the evidence says

Taurine is present in human tissues and food and participates in bile-acid conjugation, osmoregulation, calcium signaling, and other physiology. Calling it a deficiency that drives aging is a testable hypothesis, not a clinical diagnosis established by a commercial blood level.[1][3]

A 2023 Science study reported declining taurine concentrations with age in sampled species, longer lifespan in supplemented middle-aged mice, and improved selected health measures in mice and monkeys. Animal lifespan extension is meaningful preclinical evidence but does not specify a human anti-aging dose or benefit.[1]

Subsequent human cohort analyses found that circulating taurine did not consistently decline with age and in some datasets increased, weakening its use as a universal aging biomarker. NIH investigators consequently cautioned that existing evidence does not establish taurine as a biomarker of aging.[2][3]

Meta-analyses of small randomized trials report modest average improvements in blood pressure, glucose, triglycerides, and other metabolic-syndrome measures. Heterogeneity, short follow-up, and selective clinical populations mean these findings neither prove disease prevention nor validate longevity supplementation.[4][5]

Reviews call for adequately powered, long-duration human trials that measure function and clinical events. Supplement quality, kidney function, medicines that affect blood pressure or glucose, and the absence of a validated target concentration all argue against treating more taurine as automatically better.[6]

Potential benefits

  • May modestly improve selected cardiometabolic risk markers in some populations.[4][5]
  • Provides a compelling animal result for testing conserved aging mechanisms in rigorous human trials.[1]

Side effects and cautions

  • Short trials generally report good tolerability, but gastrointestinal symptoms and headache can occur and rare harms are poorly measured.[6]
  • Potential additive effects with blood-pressure or glucose-lowering treatment and uncertainty in kidney disease warrant clinical caution.[4]
How we scored it

Evidence breakdown

Mouse and primate experiments justify research, while small heterogeneous human trials address risk markers rather than aging and newer cohorts challenge the proposed age-related deficiency pattern.

Clinical relevanceLow

Human evidence centers on short-term blood pressure, glucose, and lipid markers rather than aging outcomes.

Study qualityModerate

The animal work is broad, but human trials are small and pooled across differing populations and doses.

Safety dataLow

Small trials suggest near-term tolerability; lifelong dosing, interactions, and high-risk populations are not established.

References

Full source list

  1. Taurine deficiency as a driver of aging

    Science · 2023

  2. Experimental Evidence Against Taurine Deficiency as a Driver of Aging in Humans

    Aging Cell · 2025

  3. Is taurine an aging biomarker?

    Science · 2025

  4. Effects of Oral Taurine Supplementation on Cardiometabolic Risk Factors: A Meta-analysis and Systematic Review of Randomized Clinical Trials

    Nutrition Reviews · 2025

  5. Effects of taurine supplementation on metabolic syndrome components: a systematic review and meta-analysis of randomized controlled trials

    BMC Nutrition · 2024

  6. Flattening the biological age curve by improving metabolic health: to taurine or not to taurine, that's the question

    Journal of Geriatric Cardiology · 2023